Expression of cytochrome P450 enzymes in hepatic organoid reconstructed by rat small hepatocytes

BACKGROUND AND AIMS: Small hepatocytes (SH), which are hepatic progenitor cells, were isolated from an adult rat liver. SH in a colony sometimes change their shape from small to large and from flat to rising/piled-up. The morphological changes of SH may be correlated with hepatic maturation. Cytochrome P450s (CYP) are drug-metabolizing enzymes and the expression is one of hepatic differentiated functions. However, it is well known that the re-expression and maintenance of CYP activity are very difficult in cultured hepatocytes. We investigated the expression of CYP and the enzymatic activities in long-term cultured SH. METHODS: SH were isolated from adult rat livers and SH colonies were collected, replated on new dishes, and then cultured. CYP1A1/2, CYP2B1, CYP3A2, CYP4A1, and CYP2E1 were induced by the addition of 3-methylcholanthrene, phenobarbital, pregnenolone-16alpha-carbonitrile, clofibric acid, and ethanol, respectively. Immunocytochemistry, immunoblots, and enzyme activities were examined. RESULTS: SH could differentiate into mature hepatocytes by the addition of Matrigel and re-express constitutive CYPs. The expression of CYP1A1/2, CYP2B1, CYP3A2, and CYP4A1 dose-dependently increased and the amounts gradually increased with time in culture, especially in the cells treated with Matrigel. Activities of CYP1A, CYP2B, CYP3A and CYP2E in SH treated with Matrigel induced by each of the inducers were approximately 120-fold, 2.8-fold, 6.4-fold and 0.8-fold higher than in the control. CONCLUSION: The matured SH could re-express the constitutive CYP and recover inducibility, not only of protein expression but also of enzyme activities.     

Efifcient generation of functional hepatocyte-like cells from mouse liver progenitor cells via indirect co-culture with immortalized human hepatic stellate cells

BACKGROUND: Differentiation of liver progenitor cells (LPCs) to functional hepatocytes holds great potential to de-velop new strategies for hepatocyte transplantation and the screening of drug-induced cytotoxicity. However, reports on the efifcient and convenient hepatic differentiation of LPCs to hepatocytes are few. The present study aims to investigate the possibility of generating functional hepatocytes from LPCs in an indirect co-culture system.
METHODS: Mouse LPCs were co-cultured in Transwell plates with an immortalized human hepatic stellate cell line (HSC-Li) we previously established. The morphology, expression of hepatic markers, and functions of mouse LPC-derived cells were monitored and compared with those of conventionally cultured LPCs.
RESULTS: Co-culturing with HSC-Li cells induced differentia-tion of mouse LPCs into functional hepatocyte-like cells. The differentiated cells were morphologically transformed into hepatocyte-like cells 3 days after co-culture initiation. In addi-tion, the differentiated cells expressed liver-speciifc genes and possessed hepatic functions, including glycogen storage, low-density lipoprotein uptake, albumin secretion, urea synthesis, and cytochrome P450 1A2 enzymatic activity.
CONCLUSIONS: Our method, which employs indirect co-culture with HSC-Li cells, can efifciently induce the differentiation of LPCs into functional hepatocytes. This ifnding suggests that this co-culture system can be a useful method for the efifcient generation of functional hepatocytes from LPCs.     

Update on hepatic stem cells

Abstract: The liver, like most organs in an adult healthy body, maintains a perfect balance between cell gain and cell loss. Though normally proliferatively quiescent, simple hepatocyte loss such as that caused by partial hepatectomy, uncomplicated by virus infection or inflammation, invokes a rapid regenerative response to restore liver mass. This restoration of moderate cell loss and ‘wear and tear’ renewal is largely achieved by hepatocyte self‐replication. Furthermore, cell transplant models have shown that hepatocytes can undergo significant clonal expansion. Such observations indicate that hepatocytes are the functional stem cells of the liver. More severe liver injury activates a facultative stem cell compartment located within the intrahepatic biliary tree, giving rise to cords of biliary epithelia within the lobules before these cells differentiate into hepatocytes. A third population of stem cells with hepatic potential resides in the bone marrow; these haematopoietic stem cells can contribute to the albeit low renewal rate of hepatocytes, make a more significant contribution to regeneration, and even completely restore normal function in a murine model of hereditary tyrosinaemia. How these three stem cell populations integrate to achieve a homeostatic balance is not understood. This review focuses on three aspects of liver stem cell biology: 1) the hepatic stem cell candidates; 2) models of cell transplantation into the liver; and 3) the therapeutic potential of hepatic stem cells.     

The diversity and plasticity of adult hepatic progenitor cells and their niche

The liver is a unique organ for homoeostasis with regenerative capacities. Hepatocytes possess a remarkable capacity to proliferate upon injury; however, in more severe scenarios liver regeneration is believed to arise from at least one, if not several facultative hepatic progenitor cell compartments. Newly identified pericentral stem/progenitor cells residing around the central vein is responsible for maintaining hepatocyte homoeostasis in the uninjured liver. In addition, hepatic progenitor cells have been reported to contribute to liver fibrosis and cancers. What drives liver homoeostasis, regeneration and diseases is determined by the physiological and pathological conditions, and especially the hepatic progenitor cell niches which influence the fate of hepatic progenitor cells. The hepatic progenitor cell niches are special microenvironments consisting of different cell types, releasing growth factors and cytokines and receiving signals, as well as the extracellular matrix (ECM) scaffold. The hepatic progenitor cell niches maintain and regulate stem cells to ensure organ homoeostasis and regeneration. In recent studies, more evidence has been shown that hepatic cells such as hepatocytes, cholangiocytes or myofibroblasts can be induced to be oval cell-like state through transitions under some circumstance, those transitional cell types as potential liver-resident progenitor cells play important roles in liver pathophysiology. In this review, we describe and update recent advances in the diversity and plasticity of hepatic progenitor cell and their niches and discuss evidence supporting their roles in liver homoeostasis, regeneration, fibrosis and cancers.     

Factors influencing stem cell differentiation into the hepatic lineage in vitro

Abstract   A major area of research in transplantation medicine is the potential application of stem cells in liver regeneration. This would require well-defined and efficient protocols for directing the differentiation of stem cells into the hepatic lineage, followed by their selective purification and proliferation in vitro . The development of such protocols would reduce the likelihood of spontaneous differentiation of stem cells into divergent lineages upon transplantation, as well as reduce the risk of teratoma formation in the case of embryonic stem cells. Additionally, such protocols could provide useful in vitro models for studying hepatogenesis and liver metabolism. The development of pharmokinetic and cytotoxicity/genotoxicity screening tests for newly developed biomaterials and drugs, could also utilize protocols developed for the hepatic differentiation of stem cells. Hence, this review critically examines the various strategies that could be employed to direct the differentiation of stem cells into the hepatic lineage in vitro .     

The application of organoid models in research into metabolic diseases

Metabolic diseases have become a major threat to human health worldwide as a result of changing lifestyles. The exploration of the underlying molecular mechanisms of metabolic diseases and the development of improved therapeutic methods have been hindered by the lack of appropriate human experimental models. Organoids are three-dimensional in vitro models of self-renewing cells that spontaneously self-organize into structures similar to the corresponding in vivo tissues, recapitulating the original tissue function. Off-body organoid technology has been successfully applied to disease modelling, developmental biology, regenerative medicine, and tumour precision medicine. This new generation of biological models has received widespread attention. This article focuses on the construction process and research progress with regard to organoids related to metabolic diseases in recent years, and looks forward to their prospective applications.     

骨髓源性肝干细胞和肝病

近年来，随着干细胞研究的热潮，肝干细胞也已成为消化领域中的一个热门课题。肝干细胞可界定为与肝脏胚胎发育和再生有关的各种具有干细胞特性的细胞总称，而并非指某一特定种类的细胞，可分化为具有肝细胞部分或全部表型及功能的细胞是肝干细胞的共同特点。自1999年Petersen等证明骨髓中某些干细胞具有向肝细胞分化的潜能．于是出现了“骨髓源性肝干细胞”（bone marrow derived hepatic stem cells，BDHSCs）这一概念。其后有关骨髓源性肝干细胞的分离、鉴定以及分化的多项可重复性研究成果的取得，为肝脏疾病的治疗提供了新的契机。     

Cell survival,activation and apoptosis of hepatic stellate cells: modulation by extracellular matrix proteins

Aim: Cytokines and growth factors released by various hepatic cells exert both paracrine and autocrine effects on hepatic stellate cell (HSC) activation during liver injury. The aim of the present study was to examine whether the surrounding extracellular matrix (ECM) influences the activation, transdifferentiation and survival of HSCs. Methods: An in vitro model system of isolated HSCs maintained in culture on different matrix protein substrata was employed. Results: The rate of loss of HSC‐specific retinol uptake activity and gain of myofibroblast‐like activity such as ³⁵[S] proteoglycan synthesis varied in cells maintained on different matrix proteins and was in the order collagen I > collagen IV ≥ laminin. ³[H]‐thymidine incorporation by HSCs maintained on different matrix proteins varied and was in the order collagen I > collagen IV > laminin. MTT assay revealed that the growth inhibition in response to curcumin was significantly low in cells maintained on collagen I. Apoptotic marker activities such as DNA fragmentation, 4′,6′‐diamidino‐2‐phenylindole dihydrochloride (DAPI) staining, annexin staining and caspase‐3 activities showed that cells maintained on collagen I showed minimal apoptosis than those maintained on collagen IV, laminin and polylysine, showing the influence of ECM on HSC apoptosis. Experiments using blocking antibodies showed that the collagen I effect was mediated through α₂β₁ integrin. Conclusions: These results indicate that ECM influences activation, transdifferentiation and survival of HSCs, and suggest that apart from diffusible factors, the surrounding ECM also influences HSC behavior critical in both the progression of the fibrosis and the restitution of the liver during recovery after hepatic injury.     

Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms

Aim: During fibrosis, hepatic stellate cells (HSCs) undergo a complex activation process characterized by increased proliferation and extracellular matrix deposition. Previous studies have suggested that mesenchymal stem cells (MSCs) may ameliorate fibrogenesis and represent a promising strategy for cell therapy. However, the underlying mechanisms are not fully understood. Methods: Hepatic stellate cells were treated with or without MSCs. Then cell proliferation and cell cycle were analyzed. Production of soluble factors by MSCs and its relation with cell proliferation suppression was evaluated by transwell co‐culture and RNA interference. Effects of MSCs on the gene expression of collagen were also evaluated. Results: MSCs induced G₀/G₁ arrest of HSCs growth partly through secreting soluble factors TGF‐β3 and HGF, which resulted in up‐regulation of p21^Cip1 and p27^Kip1 expression and down‐regulation of cyclinD1. MSCs inhibited the phosphorylation of extracellular signal‐regulated kinase (ERK) 1/2 and reduced gene expression of collagen type I and III. MSCs did not reverse the proliferation and collagen type I gene expression of HSCs provoked by PDGF. Conclusions: The growth inhibition of HSCs induced by MSCs through an arrest in the G₀/G₁ phase of the cell cycle is partially mediated by secretion of TGF‐β3 and HGF. MSCs inhibit HSCs activation through decreasing phosphorylation of extracellular signal‐regulated kinase (ERK) 1/2. These results further support MSCs may be used as a novel therapy for treating fibrotic diseases in human.     

胚胎干细胞体外定向分化为Ngn3+胰岛祖细胞的基因表达谱分析

目的 探讨胚胎干细胞体外定向分化为胰岛祖细胞的基因表达谱.方法 采用逐步诱导分化方案体外传代培养胚胎干细胞,应用RT-PCR和免疫细胞化学方法鉴定各分化阶段相关特异基因的表达,应用Illumina Mouse Ref-8 vl.1小鼠基因表达谱芯片测定胚胎干细胞来源的不同阶段的分化细胞(第4、8、15、20、22和25天)与未分化胚胎干细胞的基因组表达谱.结果 本研究得到了86个阶段特异性表达基因,6组具有相同表达趋势的基因簇,6组阶段差异表达基因组.从数量上看,差异表达基因最多的阶段是后前肠阶段(201个基因),接下来是定形内胚层细胞阶段(17个基因).结论 应用基因芯片对胰腺发育过程中具有相同表达趋势的基因和阶段差异表达基因的分析为早期胚胎发育和胰腺发育研究提供了试验依据.     

人骨髓间充质干细胞上清液对体外肝星状细胞增殖周期及MMP-1表达的影响

目的 研究骨髓间充质干细胞(BMSC)对肝星状细胞(HSC)增殖周期及基质金属蛋白酶-1(MMP-1)活性的影响,以探讨其防治肝纤维化的作用机制.方法 采用密度梯度离心法分离鉴定人BMSC,收集原代培养7d的BMSC培养上清,加入HSC中培养24 h及48 h.通过流式细胞仪观察HSC增殖周期,ELISA方法检测MMP-1浓度.结果 与HSC单独培养组相比,共培养48 h组G1期细胞显著增加(P＜0.01),S期细胞显著减少(P＜0.01),并且共培养组MMP-1表达明显增加,与对照组相比差异均具有统计学意义(P＜0.05).结论 BMSC可抑制HSC的增殖,并且可能通过增加MMP-1的产生,从而起到抗纤维化的作用.     

姜黄素对肝星状细胞增殖及分泌细胞外基质的影响

观察姜黄素对大鼠肝星状细胞 (HSC)增殖及分泌细胞外基质的影响。用不同浓度的姜黄素处理大鼠肝星状细胞 ;以MTT比色法测定细胞的增殖 ;放射免疫法测定透明质酸和层粘连蛋白 ;酶联免疫吸附法 (ELISA)测定Ⅰ型胶原的水平。姜黄素可剂量依赖性地抑制HSC增殖 ,不同程度抑制Ⅰ型胶原、透明质酸和层粘连蛋白分泌。姜黄素可显著抑制HSC的增殖及分泌细胞外基质。     

Relationship between hepatic progenitor cell‐mediated liver regeneration and non‐parenchymal cells

Hepatic progenitor cells (HPCs) are thought to reside in the canals of Hering and can be activated and contribute to liver regeneration in response to liver injury by proliferating and differentiating towards both hepatocytes and biliary epithelial cells. In this setting, several cytokines, chemokines, and growth factors related to liver inflammation and other liver cells comprising the HPC niche, namely hepatic stellate cells (HSCs), play crucial roles in HPC activation and differentiation. In response to several types of liver injury, tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) is secreted by several inflammatory cells, including monocytes, T lymphocytes, and macrophages, and acts as an initiator of the HPC niche and HSC activation. Following TWEAK‐induced activation of the HPC niche, fibroblast growth factor 7 and hepatocyte growth factor released from activated HSC play central roles in maintaining HPC proliferation. In contrast, HGF‐MET and Wnt3a‐β‐catenin signals are the predominant mediators of the hepatocyte differentiation of HPC, whereas epidermal growth factor receptor–NOTCH signaling controls HPC differentiation towards biliary epithelial cells. These signals are maintained exclusively by activated HSC and inflammatory cells surrounding HPC. Together, HSC and inflammatory cells surrounding HPC are responsible for the precise control of HPC proliferation and differentiation fate. In this review, we discuss recent progress in understanding of interactions between HPC and other liver cells in HPC‐mediated liver regeneration in the setting of liver inflammation.     

Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy

Hepatic fibrosis is a wound-healing response to chronic liver injury, which if persistent leads to cirrhosis and liver failure. Exciting progress has been made in understanding the mechanisms of hepatic fibrosis. Major advances include: (i) characterization of the components of extracellular matrix (ECM) in normal and fibrotic liver; (ii) identification of hepatic stellate cells as the primary source of ECM in liver fibrosis; (iii) elucidation of key cytokines, their cellular sources, modes of regulation, and signalling pathways involved in liver fibrogenesis; (iv) characterization of key matrix proteases and their inhibitors; (v) identification of apoptotic mediators in stellate cells and exploration of their roles during the resolution of liver injury. These advances have helped delineate a more comprehensive picture of liver fibrosis in which the central event is the activation of stellate cells, a transformation from quiescent vitamin A-rich cells to proliferative, fibrogenic and contractile myofibroblasts. The progress in understanding fibrogenic mechanisms brings the development of effective therapies closer to reality. In the future, targeting of stellate cells and fibrogenic mediators will be a mainstay of antifibrotic therapy. Points of therapeutic intervention may include: (i) removing the injurious stimuli; (ii) suppressing hepatic inflammation; (iii) down-regulating stellate cell activation; and (iv) promoting matrix degradation. The future prospects for effective antifibrotic treatment are more promising than ever for the millions of patients with chronic liver disease worldwide.